← Eichor
Condition: Melanoma Stage Iv Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Melanoma Stage Iv

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Phase 2 · 1 location(s) · Kevin Kim, MD · NCT07237100Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers
NA · 1 location(s) · Institute of Oncology Ljubljana · NCT07407166Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresecta
Phase 2 · 1 location(s) · Philogen S.p.A. · NCT06284590A Study of ST-1898 for Unresectable or Metastatic Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Scitech-Mq Pharmaceuticals Limited · NCT06359860A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Krystal Biotech, Inc. · NCT05970497A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
Phase 2 · 12 location(s) · Memorial Sloan Kettering Cancer Center · NCT06594991BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Phase 3 · 30 location(s) · Canadian Cancer Trials Group · NCT02821013Efficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage III/IV Melanoma.
EARLY_Phase 1 · 1 location(s) · Xijing Hospital · NCT07586904Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05155033NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma
Phase 2 · 1 location(s) · Oslo University Hospital · NCT06651151FMT to Convert Response to Immunotherapy
Phase 1/Phase 2 · 1 location(s) · The Netherlands Cancer Institute · NCT05251389Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Phase 1/Phase 2 · 11 location(s) · Georgiamune Inc · NCT06425926Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
Phase 2 · 1 location(s) · University of California, Irvine · NCT06771544A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
Phase 2 · 1 location(s) · Fudan University · NCT06889610T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Phase 1 · 1 location(s) · Inge Marie Svane · NCT06783270NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
Phase 1 · 2 location(s) · Centre Hospitalier Universitaire Vaudois · NCT06889766Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
EARLY_Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04741997Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
Phase 2 · 3 location(s) · Abramson Cancer Center at Penn Medicine · NCT03646617Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07627698In Vivo Liquid Biopsy of Melanoma (Cytophone)
NA · 1 location(s) · Cytoastra · NCT06488365Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Phase 1/Phase 2 · 10 location(s) · Obsidian Therapeutics, Inc. · NCT06060613Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
Phase 1 · 2 location(s) · St Vincent's Hospital, Sydney · NCT07203391Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain
Phase N/A · 39 location(s) · Grupo Español Multidisciplinar de Melanoma · NCT03605771Dabrafenib and/or Trametinib Rollover Study
Phase 4 · 32 location(s) · Novartis Pharmaceuticals · NCT03340506Urinary Microbiome as a Biomarker for Melanoma Diagnosis and Response Prediction to Systemic Tumour Therapy
Phase N/A · 1 location(s) · Medical University of Graz · NCT07635732Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
Phase 2 · 1 location(s) · Sheba Medical Center · NCT05909618Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Mela
Phase 3 · 15 location(s) · ETOP IBCSG Partners Foundation · NCT05522660A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiat
Phase 1 · 2 location(s) · Memorial Sloan Kettering Cancer Center · NCT05607095Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME T
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT04693377
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.